Retina/Vitreous News

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, elucidates complications that may occur following gene therapy with Luxturna.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Giovanni Staurenghi, MD, discusses high-resolution OCT.

ROME — In this Healio Video Perspective at the FLORetina-ICOOR meeting, Giuseppe Querques, MD, PhD, discusses phenotypes of intermediate AMD that help physicians predict geographic atrophy development and progression.

Food or housing insecurity, mental health and cultural understanding with the practitioner are among the barriers to receiving regular diabetic retinopathy screenings, according to research published in JAMA Ophthalmology.

ROME — In this Healio Video Perspective at the FLORetina-ICOOR meeting, James G. Fujimoto, PhD, speaks about advancements in high resolution spectral-domain OCT.

Artificial intelligence-based screening systems can be key in making diabetic retinopathy screening more accessible, financially viable and effective in terms of outcomes, according to one specialist at the FLORetina-ICOOR meeting.

RetinalGeniX has contracted with Medsan to provide diagnostic testing for a study on personalizing medical evaluations for patients with wet age-related macular degeneration.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Jean-François Korobelnik, MD, PhD, reflects on how retina specialists are going to use high-dose aflibercept in real-world practice.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Ursula Schmidt-Erfurth, MD, shares her knowledge and firsthand experience with AI-based OCT analysis of geographic atrophy.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Michael Stewart, MD, speaks about aflibercept 8 mg, the newly approved version of Eylea.